Cigna Group (NYSE:CI) Issues Earnings Results, Beats Estimates By $0.18 EPS

Cigna Group (NYSE:CI) issued its quarterly earnings data on Thursday. The health services provider reported $7.78 EPS for the quarter, topping analysts’ consensus estimates of $7.60 by $0.18, Zacks reports. Cigna Group had a return on equity of 19.75% and a net margin of 2.26%.The firm had revenue of $70.04 billion during the quarter, compared to the consensus estimate of $70.14 billion. During the same period in the prior year, the business earned $7.20 EPS. The firm’s revenue was up 6.7% on a year-over-year basis. Cigna Group updated its FY 2026 guidance to 30.450- EPS.

Here are the key takeaways from Cigna Group’s conference call:

• Second-quarter results exceeded expectations: revenue reached $71.7 billion and adjusted EPS was $7.78, prompting Cigna to raise its 2026 adjusted EPS outlook to at least $30.45.
• Evernorth Specialty and Care Services adjusted earnings grew 22% year over year to $1.1 billion, supported by specialty utilization, faster biosimilar and specialty-generic adoption, operating efficiencies, and contributions from Shields Health Solutions.
• Cigna Healthcare adjusted earnings rose 17%, with membership growth in the U.S. employer business and slightly favorable medical-cost experience; full-year segment earnings guidance increased to at least $4.55 billion.
• Evernorth Pharmacy Benefit Services earnings declined to $609 million due to large contract renewals and investments in the rebate-free Signature model, while moderating GLP-1 utilization and faster biosimilar adoption are expected to pressure the business through the rest of 2026.
• Management continues investing in AI-enabled programs such as Pharmacy Forward and enhanced care coordination, which it says could cut specialty therapy-start times in half, support 20% more customers with complex needs, and reduce avoidable inpatient stays.

Cigna Group Price Performance

Cigna Group stock traded down $8.91 during trading hours on Thursday, hitting $287.56. 2,320,486 shares of the company traded hands, compared to its average volume of 1,680,586. Cigna Group has a 1-year low of $239.51 and a 1-year high of $315.47. The firm has a market cap of $76.07 billion, a P/E ratio of 12.19, a P/E/G ratio of 1.16 and a beta of 0.29. The firm’s 50-day simple moving average is $286.75 and its two-hundred day simple moving average is $281.12. The company has a quick ratio of 0.73, a current ratio of 0.73 and a debt-to-equity ratio of 0.69.

Cigna Group Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Tuesday, September 8th will be paid a dividend of $1.56 per share. The ex-dividend date of this dividend is Tuesday, September 8th. This represents a $6.24 annualized dividend and a yield of 2.2%. Cigna Group’s dividend payout ratio (DPR) is presently 26.45%.

Trending Headlines about Cigna Group

Here are the key news stories impacting Cigna Group this week:

• Positive Sentiment: Cigna reported second-quarter adjusted earnings of $7.78 per share, exceeding the $7.60 consensus estimate and rising from $7.20 a year earlier. Revenue increased approximately 7% year over year to about $71.7 billion. CI Q2 Earnings Beat Estimates on Cigna Healthcare Strength
• Positive Sentiment: The company raised its 2026 adjusted earnings outlook to at least $30.45 per share, slightly above the roughly $30.40 analyst consensus. Growth was broad-based, with Cigna Healthcare revenue up 9% and Evernorth Health Services revenue up 6% year over year. Cigna raises annual profit forecast on strength in health services unit
• Neutral Sentiment: Net income reached nearly $1.7 billion, or $6.29 per share, while adjusted operating income was $2.1 billion. The results indicate continued operating strength, although reported revenue was modestly below one estimate of $70.14 billion, depending on the company’s reporting measure used. The Cigna Group Reports Strong Second Quarter 2026 Results
• Negative Sentiment: Management expects lower growth in prescriptions for popular GLP-1 drugs, while higher pharmacy costs remain a concern. Those comments appear to be tempering the market’s reaction to the earnings beat and guidance increase. Cigna Expects Lower Growth in Popular GLP-1 Drug Prescriptions

Insider Activity at Cigna Group

In other Cigna Group news, CEO David Cordani sold 201,878 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $292.82, for a total value of $59,113,915.96. Following the completion of the sale, the chief executive officer directly owned 34,337 shares in the company, valued at $10,054,560.34. This represents a 85.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Jamie G. Kates sold 899 shares of the stock in a transaction on Friday, June 12th. The shares were sold at an average price of $298.61, for a total value of $268,450.39. Following the transaction, the chief accounting officer directly owned 2,368 shares of the company’s stock, valued at approximately $707,108.48. The trade was a 27.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.60% of the company’s stock.

Institutional Trading of Cigna Group

Hedge funds and other institutional investors have recently modified their holdings of the company. Wilkerson Advisory Group LLC acquired a new stake in shares of Cigna Group in the fourth quarter valued at $25,000. Prosperity Bancshares Inc acquired a new position in Cigna Group during the fourth quarter worth about $29,000. Kemnay Advisory Services Inc. bought a new stake in Cigna Group in the fourth quarter worth about $29,000. Measured Wealth Private Client Group LLC acquired a new stake in Cigna Group in the 3rd quarter valued at about $56,000. Finally, Johnson Financial Group Inc. boosted its position in shares of Cigna Group by 445.9% during the 3rd quarter. Johnson Financial Group Inc. now owns 202 shares of the health services provider’s stock valued at $58,000 after purchasing an additional 165 shares in the last quarter. Institutional investors own 86.99% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on CI. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Cigna Group in a report on Monday, June 1st. Guggenheim upped their target price on shares of Cigna Group from $334.00 to $338.00 and gave the stock a “buy” rating in a research report on Monday, May 4th. Deutsche Bank Aktiengesellschaft lowered shares of Cigna Group from a “buy” rating to a “hold” rating and dropped their price target for the company from $303.00 to $302.00 in a research note on Wednesday, May 20th. Robert W. Baird set a $337.00 price target on Cigna Group in a report on Friday, May 1st. Finally, Wolfe Research reiterated an “outperform” rating and set a $315.00 price objective on shares of Cigna Group in a research report on Tuesday, June 16th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, Cigna Group has an average rating of “Moderate Buy” and a consensus price target of $338.80.

Cigna Group Company Profile

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.